Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.
종목 코드 ANIK
회사 이름Anika Therapeutics Inc
상장일May 16, 1985
CEODr. Cheryl Renee Blanchard, Ph.D.
직원 수288
유형Ordinary Share
회계 연도 종료May 16
주소32 Wiggins Ave
도시BEDFORD
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호01730-2315
전화17814579000
웹사이트https://anika.com/
종목 코드 ANIK
상장일May 16, 1985
CEODr. Cheryl Renee Blanchard, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음